Qin-Yan Chen1, Tim J Harrison2, Caroline A Sabin3, Guo-Jian Li4, Gao-Ming Huang5, Jin-Ye Yang1, Xue-Yan Wang1, Hai Li1, Mo-Han Liu6, Zhong-Liao Fang6. 1. Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Nanning, China. 2. Division of Medicine, Faculty of Medical Sciences, University College London, London, UK. 3. Research Department of Infection and Population Health, UCL Medical School, London, UK. 4. Department of Public Health of Guangxi Zhuang Autonomous Region, Nanning, China. 5. School of Public Health, Guangxi Medical University, Nanning, China. 6. Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Nanning, China ; School of Preclinical Medicine, Guangxi Medical University, Nanning, China.
Abstract
BACKGROUND: Association of hepatitis B virus (HBV) genotype C with hepatocellular carcinoma (HCC) development remains controversial. HBV basal core promoter (BCP) double mutations (T(1762)A(1764)) are very strong confounding factors of genotypes B and C in HCC development. OBJECTIVES: To investigate the association of HBV genotype C with HCC development after controlling for BCP double mutations. MATERIALS AND METHODS: Four hundred and two serum samples from patients with HCC, liver cirrhosis (LC) and chronic hepatitis (CH) and also from asymptomatic HBsAg carriers were analyzed. RESULTS: Genotypes B (31.1%), C (62.8%), and I (6.1%) were detected. With the severity of liver disease the prevalence of genotype B decreased, but genotype C increased. No trend was found for genotype I. The prevalence of BCP double mutations in genotypes C and I viruses was significantly higher than genotype B. BCP double mutations are risk factors for CH, LC and HCC. Genotype C was not identified as a particular risk factor for HCC prior to the stratification analysis but after that genotype C viruses with BCP double mutations were found to be a particular risk factor for HCC (P = 0.008, OR = 17.19 [95% CI: 2.10 - 140.41]), but those with the wild-type BCP were not. In the interaction analysis, genotype C and BCP double mutations were found to have a synergistic effect on HCC development (P < 0.0001, OR = 52.56 [95% CI: 11.49-240.52]). CONCLUSIONS: The effect of HBV genotype C on the development of HCC differs between wild-type viruses and those with BCP double mutations, suggesting that not all individuals infected with genotype C HBV are at increased risk of HCC.
BACKGROUND: Association of hepatitis B virus (HBV) genotype C with hepatocellular carcinoma (HCC) development remains controversial. HBV basal core promoter (BCP) double mutations (T(1762)A(1764)) are very strong confounding factors of genotypes B and C in HCC development. OBJECTIVES: To investigate the association of HBV genotype C with HCC development after controlling for BCP double mutations. MATERIALS AND METHODS: Four hundred and two serum samples from patients with HCC, liver cirrhosis (LC) and chronic hepatitis (CH) and also from asymptomatic HBsAg carriers were analyzed. RESULTS: Genotypes B (31.1%), C (62.8%), and I (6.1%) were detected. With the severity of liver disease the prevalence of genotype B decreased, but genotype C increased. No trend was found for genotype I. The prevalence of BCP double mutations in genotypes C and I viruses was significantly higher than genotype B. BCP double mutations are risk factors for CH, LC and HCC. Genotype C was not identified as a particular risk factor for HCC prior to the stratification analysis but after that genotype C viruses with BCP double mutations were found to be a particular risk factor for HCC (P = 0.008, OR = 17.19 [95% CI: 2.10 - 140.41]), but those with the wild-type BCP were not. In the interaction analysis, genotype C and BCP double mutations were found to have a synergistic effect on HCC development (P < 0.0001, OR = 52.56 [95% CI: 11.49-240.52]). CONCLUSIONS: The effect of HBV genotype C on the development of HCC differs between wild-type viruses and those with BCP double mutations, suggesting that not all individuals infected with genotype C HBV are at increased risk of HCC.
Authors: Elisabetta Franco; Barbara Bagnato; Maria Giulia Marino; Cristina Meleleo; Laura Serino; Laura Zaratti Journal: World J Hepatol Date: 2012-03-27
Authors: Anna Kramvis; Karin Restorp; Heléne Norder; Johan F Botha; Lars O Magnius; Michael C Kew Journal: J Med Virol Date: 2005-09 Impact factor: 2.327
Authors: Magdalena Świderska; Małgorzata Pawłowska; Włodzimierz Mazur; Krzysztof Tomasiewicz; Krzysztof Simon; Anna Piekarska; Marta Wawrzynowicz-Syczewska; Jerzy Jaroszewicz; Paweł Rajewski; Ewelina Zasik; Elżbieta Murias-Bryłowska; Anna Pniewska; Waldemar Halota; Robert Flisiak Journal: Clin Exp Hepatol Date: 2015-04-30